- Home
- CRGX vs PHAR Comparison
CRGX vs PHAR Comparison
Compare CRGX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- PHAR
- Stock Information
- Founded
- CRGX 2021
- PHAR 1988
- Country
- CRGX United States
- PHAR Netherlands
- Employees
- CRGX N/A
- PHAR N/A
- Industry
- CRGX
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- PHAR Health Care
- Exchange
- CRGX Nasdaq
- PHAR Nasdaq
- Market Cap
- CRGX 621.4M
- PHAR 679.0M
- IPO Year
- CRGX 2023
- PHAR N/A
- Fundamental
- Price
- CRGX $13.46
- PHAR $9.10
- Analyst Decision
- CRGX Strong Buy
- PHAR Strong Buy
- Analyst Count
- CRGX 6
- PHAR 3
- Target Price
- CRGX $31.80
- PHAR $27.00
- AVG Volume (30 Days)
- CRGX 235.6K
- PHAR 6.7K
- Earning Date
- CRGX 03-20-2025
- PHAR 03-13-2025
- Dividend Yield
- CRGX N/A
- PHAR N/A
- EPS Growth
- CRGX N/A
- PHAR N/A
- EPS
- CRGX N/A
- PHAR N/A
- Revenue
- CRGX N/A
- PHAR $285,745,000.00
- Revenue This Year
- CRGX N/A
- PHAR $20.08
- Revenue Next Year
- CRGX N/A
- PHAR $9.22
- P/E Ratio
- CRGX N/A
- PHAR N/A
- Revenue Growth
- CRGX N/A
- PHAR 30.64
- 52 Week Low
- CRGX $10.91
- PHAR $6.65
- 52 Week High
- CRGX $33.92
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- CRGX 47.00
- PHAR 46.44
- Support Level
- CRGX $12.51
- PHAR $9.37
- Resistance Level
- CRGX $15.75
- PHAR $10.01
- Average True Range (ATR)
- CRGX 1.09
- PHAR 0.55
- MACD
- CRGX 0.17
- PHAR -0.14
- Stochastic Oscillator
- CRGX 52.74
- PHAR 16.26
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.